|
1
|
Dotan A, Dadia S, Bickels J, Nirkin A,
Flusser G, Issakov J, Neumann Y, Cohen I, Ben-Arush M, Kollender Y,
et al: Expandable endoprosthesis for limb-sparing surgery in
children: Long-term results. J Child Orthop. 4:391–400. 2010.
View Article : Google Scholar :
|
|
2
|
Broadhead ML, Clark JC, Myers DE, Dass CR
and Choong PF: The molecular pathogenesis of osteosarcoma: A
review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
4
|
Ottaviani G and Jaffe N: The etiology of
osteosarcoma. Cancer Treat Res. 152:15–32. 2009. View Article : Google Scholar
|
|
5
|
Weiss RB: The anthracylcines: Will we ever
find a better doxorubicin? Semin Oncol. 19:670–686. 1992.PubMed/NCBI
|
|
6
|
Thorna CF, Oshiroa C, Marshe S,
Hernandez-Boussard T, McLeod H, Kleina TE and Altman RB:
Doxorubicin pathways: Pharmacodynamics and adverse effects.
Pharmacogenet Genomics. 21:440–446. 2011. View Article : Google Scholar
|
|
7
|
Beklemisheva AA, Fang Y, Feng J, Ma X, Dai
W and Chiao JW: Epigenetic mechanism of growth inhibition induced
by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer
Res. 26:1225–1230. 2006.PubMed/NCBI
|
|
8
|
Ma X, Fang Y, Beklemisheva A, Dai W, Feng
J, Ahmed T, Liu D and Chiao JW: Phenylhexyl isothiocyanate inhibits
histone deacetylases and remodels chromatins to induce growth
arrest in human leukemia cells. Int J Oncol. 28:1287–1293.
2006.PubMed/NCBI
|
|
9
|
Lu Q, Lin X, Feng J, Zhao X, Gallagher R,
Lee MY, Chiao JW and Liu D: Phenylhexyl isothiocyanate has dual
function as histone deacetylase inhibitor and hypomethylating agent
and can inhibit myeloma cell growth by targeting critical pathways.
J Hematol Oncol. 9:1–6. 2008.
|
|
10
|
Stan SD, Singh SV, Whitcomb DC and Brand
RE: Phenethyl isothiocyanate inhibits proliferation and induces
apoptosis in pancreatic cancer cells in vitro and in a MIAPaca2
xenograft animal model. Nutr Cancer. 66:747–755. 2014.Nov 6 2013
[Epub ahead of print]. View Article : Google Scholar :
|
|
11
|
Huang SH, Hsu MH, Hsu SC, Yang JS, Huang
WW, Huang AC, Hsiao YP, Yu CC and Chung JG: Phenethyl
isothiocyanate triggers apoptosis in human malignant melanoma
A375.S2 cells through reactive oxygen species and the
mitochondria-dependent pathways. Hum Exp Toxicol. 33:270–283. 2014.
View Article : Google Scholar
|
|
12
|
Sarkars R, Mukherjee S and Roy M:
Targeting heat shock proteins by phenethyl isothiocyanate results
in cell-cycle arrest and apoptosis of human breast cancer cells.
Nutr Cancer. 65:480–493. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiao D and Singh SV: p66Shc is
indispensable for phenethyl isothiocyanate-induced apoptosis in
human prostate cancer cells. Cancer Res. 70:3150–3158. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cang S, Ma Y, Chiao JW and Liu D:
Phenethyl isothiocyanate and paclitaxel synergistically enhanced
apoptosis and alpha-tubulin hyperacetylation in breast cancer
cells. Exp Hematol Oncol. 3:52014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee DH, Kim DW, Lee HC, Lee JH and Lee TH:
Phenethyl isothiocyanate sensitizes glioma cells to TRAIL-induced
apoptosis. Biochem Biophys Res Commun. 446:815–521. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang T, Song X, Liu YF and Wang WY: PEITC
reverse multi-drug resistance of human gastric cancer SGC7901/DDP
cell line. Cell Biol Int. 38:502–510. 2014. View Article : Google Scholar
|
|
17
|
Liu K, Cang S, Ma Y and Chiao JW:
Synergistic effect of paclitaxel and epigenetic agent phenethyl
isothiocyanate on growth inhibition, cell cycle arrest and
apoptosis in breast cancer cells. Cancer Cell Int. 13:102013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiao D and Singh SV: Phenethyl
isothiocyanate sensitizes androgen-independent human prostate
cancer cells to docetaxel-induced apoptosis in vitro and in vivo.
Pharm Res. 27:722–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gupta P and Srivastava SK: Antitumor
activity of phenethyl isothiocyanate in HER2-positive breast cancer
models. BMC Med. 10:802012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuang P, Chen BA, Cheng J, Ma XD, Liu DL
and Lu QY: Effect of phenylhexyl isothiocyanate on adriamycin
resistance of K562/A02 cell line. Zhongguo Shi Yan Xue Ye Xue Za
Zhi. 17:352–357. 2009.In Chinese. PubMed/NCBI
|
|
21
|
Mukherjee S, Bhattacharya RK and Roy M:
Targeting protein kinase C (PKC) and telomerase by phenethyl
isothiocyanate (PEITC) sensitizes PC-3 cells towards
chemotherapeutic drug-induced apoptosis. J Environ Pathol Toxicol
Oncol. 28:269–282. 2009. View Article : Google Scholar
|
|
22
|
Massart C, Barbet R, Genetet N and
Gibassier J: Doxorubicin induces Fas-mediated apoptosis in human
thyroid carcinoma cells. Thyroid. 14:263–270. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wennerberg E, Sarhan D, Carlsten M,
Kaminskyy VO, D'Arcy P, Zhivotovsky B, Childs R and Lundqvist A:
Doxorubicin sensitizes human tumor cells to NK cell- and
T-cell-mediated killing by augmented TRAIL receptor signaling. Int
J Cancer. 133:1643–1652. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Degterev A, Boyce M and Yuan J: A decade
of caspases. Oncogene. 22:8543–8567. 2003. View Article : Google Scholar : PubMed/NCBI
|
